Physician
MPL INC
MPL INC was paid $43K by Medicaid between Nov 2021 and Oct 2024, across 37 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 17% of everything it billed.
33Billing provider infoMPL INC
LONGVIEW, TX 75601
LONGVIEW, TX 75601
33aNPI1568439313assigned 03/01/2006
33bProvider typeCytopathology Physician
28Total paid$43K
24GClaims11,468
24DCodes billed37
24AFirst – last monthNov 2021 – Oct 2024
Compared with peers
Next to other Cytopathology Physician providers in Texas
Rank by total paid#8 of 14
Median peer was paid$43K
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 51 | $0.00 | |
| 2022 | 7,299 | $37K | |
| 2023 | 511 | $1K | |
| 2024incomplete | 3,607 | $5K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 17% | 1,255 | 928 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 17% | 1,253 | 924 | $7K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 16% | 1,035 | 735 | $7K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 7.0% | 592 | 513 | $3K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 5.8% | 763 | 416 | $2K |
| 87481 | 4.5% | 756 | 308 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 4.4% | 521 | 259 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.5% | 340 | 104 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.8% | 532 | 455 | $1K |
| 86762 | 2.5% | 225 | 197 | $1K | |
| 87511 | 2.2% | 408 | 311 | $953.16 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 646 | 566 | $870.00 |
25 more codes
| 86850 | 1.8% | 240 | $758.04 | |
| 86780 | 1.7% | 275 | $732.68 | |
| 86803 | 1.5% | 266 | $623.31 | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 1.4% | 13 | $605.72 |
| 87340 | 1.4% | 297 | $597.74 | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 147 | $560.14 |
| 82105 | <1% | 187 | $423.49 | |
| 84702 | <1% | 51 | $273.67 | |
| 86787 | <1% | 80 | $257.52 | |
| 86900 | <1% | 254 | $242.08 | |
| 86901 | <1% | 254 | $234.94 | |
| 87081 | <1% | 207 | $225.43 | |
| 86592 | <1% | 161 | $204.64 | |
| 87186 | <1% | 30 | $158.50 | |
| 82950 | <1% | 189 | $140.14 | |
| 82570 | <1% | 79 | $108.53 | |
| 82951 | <1% | 34 | $75.67 | |
| 85027 | <1% | 42 | $64.62 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 33 | $56.71 |
| 87077 | <1% | 13 | $53.98 | |
| 80053 | Comprehensive metabolic panel | <1% | 18 | $36.06 |
| 82947 | <1% | 66 | $35.98 | |
| 81001 | <1% | 121 | $23.03 | |
| 82952 | <1% | 34 | $23.03 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOLIVER, BRIAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Gulf Coast Pathology Associates PLLC | Houston, TX | $2.11M |
| Arbor Diagnostics INC | Dallas, TX | $1.59M |
| Northern Michigan Chiropractic Center, PLC | Gaylord, MI | $94K |
| Med Path Labs INC | Longview, TX | $1K |
| Gulf Coast Pathology Associates PLLC | Houston, TX | $937.71 |
| Arbor Diagnostics INC | Dallas, TX | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.